Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials

Over 2,200 patients infected with hepatitis C virus (HCV) genotypes (GT) 1 to 6, with or without cirrhosis, who were treatment naive or experienced to interferon, ribavirin, and/or sofosbuvir were treated with glecaprevir/pibrentasvir for 8, 12, or 16 weeks in eight registrational phase 2 and 3 clin...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Krishnan, Preethi, Pilot-Matias, Tami, Schnell, Gretja, Tripathi, Rakesh, Ng, Teresa I., Reisch, Thomas, Beyer, Jill, Dekhtyar, Tatyana, Irvin, Michelle, Xie, Wangang, Larsen, Lois, Mensa, Federico J., Collins, Christine
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2018
Sujets:
Antiviral Agents
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6153825/
https://ncbi.nlm.nih.gov/pubmed/30061289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01249-18
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires